Dr Reddys Laboratories Ltd has sent a clarification with respect to the media report which appeared in "Financial Chronicle" dated November 27, 2014 titled "Srikakulam plant gets Form 483 for lapses: DRL."

The Company clarified stating that the company had received some inspectional observations from the US FDA after their visit to their API manufacturing facility in Srikakulam district of Andhra Pradesh The company is committed to respond to the agency within stipulated timelines with their remedial plans and start implementing the necessary measures immediately. At this stage, it has no implication on any activity at the plant. Hence, these are not expected to be material to the Companys operations or consolidated results.

Source : BSE - >

Published on November 27, 2014


This article is closed for comments.
Please Email the Editor